Co-Authors
This is a "connection" page, showing publications co-authored by CHERYL WALKER and NIZAR M TANNIR.
Connection Strength
0.864
-
Molecular hallmarks of renal medullary carcinoma: more to c-MYC than meets the eye. Mol Cell Oncol. 2020; 7(5):1777060.
Score: 0.192
-
Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma. Clin Genitourin Cancer. 2019 02; 17(1):1-6.
Score: 0.170
-
A Model Linking Sickle Cell Hemoglobinopathies and SMARCB1 Loss in Renal Medullary Carcinoma. Clin Cancer Res. 2018 05 01; 24(9):2044-2049.
Score: 0.163
-
SMARCB1 regulates the hypoxic stress response in sickle cell trait. Proc Natl Acad Sci U S A. 2023 05 23; 120(21):e2209639120.
Score: 0.059
-
Neddylation inhibition sensitises renal medullary carcinoma tumours to platinum chemotherapy. Clin Transl Med. 2023 05; 13(5):e1267.
Score: 0.058
-
Association of High-Intensity Exercise with Renal Medullary Carcinoma in Individuals with Sickle Cell Trait: Clinical Observations and Experimental Animal Studies. Cancers (Basel). 2021 Nov 30; 13(23).
Score: 0.053
-
Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary Carcinoma. Cancer Cell. 2020 05 11; 37(5):720-734.e13.
Score: 0.047
-
p53 Is a Master Regulator of Proteostasis in SMARCB1-Deficient Malignant Rhabdoid Tumors. Cancer Cell. 2019 02 11; 35(2):204-220.e9.
Score: 0.044
-
HNF1B Loss Exacerbates the Development of Chromophobe Renal Cell Carcinomas. Cancer Res. 2017 10 01; 77(19):5313-5326.
Score: 0.039
-
Renal Medullary Carcinoma: Establishing Standards in Practice. J Oncol Pract. 2017 07; 13(7):414-421.
Score: 0.039